Tianjin Medical University Second Hospital
Clinical trials sponsored by Tianjin Medical University Second Hospital, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Urine test may spare bladder cancer patients from unnecessary second surgery Results expected Nov 2026 (estimated)
- New drug combo aims to save kidneys in pelvic cancer patients Results expected Dec 2026 (estimated)
- New drug cocktail shows promise for Tough-to-Treat urinary tract cancer Results expected Dec 2026 (estimated)
- Simple blood and urine test could spot bladder cancer return Results expected Jan 2027 (estimated)
- New drug duo takes on tough prostate cancers Results expected Jun 2027 (estimated)
-
Could an immunotherapy drug keep kidney cancer from returning after surgery?
Disease control OngoingThis phase 2 trial is testing whether toripalimab, an immunotherapy drug, can prevent high-risk kidney cancer from coming back after surgery to remove the kidney. About 100 participants will receive the drug every three weeks for up to a year. Researchers will track how long they…
Phase 2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
AI model aims to predict recovery after Kidney-Sparing surgery
Knowledge-focused OngoingThis study looks at whether combining CT scan images, tumor features, and patient health information can better predict how well people recover after partial nephrectomy for endophytic kidney cancer. Researchers will analyze data from 406 patients who have already had surgery to …
Sponsor: Tianjin Medical University Second Hospital • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC